Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01807 |
NKp44/NCR2 Protein, Human, Recombinant (His)
RP1-149M18.2,LY95,dJ149M18.1,NK-p44,CD336,... |
Human | HEK293 Cells |
NKp44/NCR2 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 20 kDa and the accession number is O95944-1. | |||
TMPJ-00102 |
CD28 Protein, Human/Cynomolgus, Recombinant (hFc & Avi), Biotinylated
CD28 molecule,CD28 antigen,CD28,T... |
Human,Cynomolyus | HEK293 Cells |
CD28 Protein, Human/Cynomolgus, Recombinant (hFc & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-Fc-Avi tag. The predicted molecular weight is 60-90 KDa and the accession number is P10747. | |||
TMPK-00183 |
CD20 Protein, Human, Recombinant (His & Avi)
MS4A2,Ly-44,LEU-16,MS4A1,Bp35,CD20 recepto... |
Human | E. coli |
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases. CD20... | |||
TMPY-05367 |
NKp44/NCR2 Protein, Human, Recombinant (His), Biotinylated
RP1-149M18.2,CD336,natural cytotoxicity triggering ... |
Human | HEK293 Cells |
NKp44/NCR2 Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 20 kDa and the accession number is O95944-1. | |||
TMPK-00518 |
CD44 Protein, Cynomolgus, Recombinant (His)
CDw44,IN,MIC4,CD44,ECMR-... |
Cynomolgus | HEK293 Cells |
CD44 is a hyaluronan binding cell surface signal transducing receptor that influences motility, cell survival and proliferation as well as the formation of tumor microenvironment. CD44 contains two variable regions encoded by variable exons. Alternative splicing, which is often deregulated in cancer, can produce various isoforms of CD44 with properties that may have different tissue specific effects and therefore even diverse effects on cancer progression |